Eric Joseph Daniels - Feb 1, 2022 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role
Chief Development Officer
Signature
/s/ Sarah Romano, Attorney-in-Fact*
Stock symbol
KPRX
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 06:03 PM
Previous filing
Nov 10, 2021
Next filing
Oct 25, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPRX Stock Option (right to buy) Award $0 +25K $0.00 25K Feb 1, 2022 Common Stock 25K $0.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.